# ZNTL — Zentalis Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ZNTL  
**Sources:** 11  
**Published:** 2026-10-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-zntl-zentalis-pharmaceuticals-inc-catalysts-narrative-ri-10073

---

## Overview and Recent Trading Context

As of the close on October 29, 2026, ZNTL traded at $1.99, down 3.40% for the day, with extended-trading prices around $2.00–$2.02 [[6]](https://stockanalysis.com/stocks/zntl/forecast/). On a market-cap basis, the company was valued at roughly USD 185.4 million as of October 1, 2026, within a 52-week price range of USD 1.21 to USD 6.95 [[2]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/wells-fargo-sets-usd-5-00-target-for-zentalis-pharmaceuticals-stock/70213730). (This is consistent with, though not an exact confirmation of, the prior-knowledge snapshot of ~$195.26M dated October 30, 2026.) The company is a clinical-stage oncology developer whose lead candidate is azenosertib, an oral WEE1 inhibitor [[3]](https://www.marketbeat.com/earnings/reports/2026-11-10-zentalis-pharmaceuticals-inc-stock/)[[5]](https://www.biospace.com/press-releases/zentalis-pharmaceuticals-reports-second-quarter-2026-financial-results-and-business-updates).

## Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-zntl-zentalis-pharmaceuticals-inc-catalysts-narrative-ri-10073 (free to sign up)._